Gut Hormone FGF15 Influences Muscle, Bone, and Bile Acids During Weight Loss
Background
Weight loss, while beneficial for metabolic health, often leads to undesirable side effects such as the loss of lean mass (muscle) and a decrease in bone mineral density. Concurrently, bile acid metabolism, crucial for nutrient absorption and signaling, undergoes significant changes during periods of caloric restriction. Despite extensive research into the systemic effects of weight loss, the precise mechanisms by which gut-derived factors communicate with peripheral tissues to modulate these responses remain incompletely understood. This study specifically addresses how gut-derived Fibroblast Growth Factor 15 (FGF15) influences lean mass, bone health, and bile acid profiles during weight loss.
Results
The study revealed a critical role for FGF15 in preserving lean mass and bone health during weight loss. During caloric restriction, FGF15 knockout mice exhibited significantly reduced lean mass preservation, showing a 15% greater loss of lean body mass compared to wild-type controls (p<0.01). Furthermore, bone health was severely compromised in the absence of FGF15, with FGF15 KO mice experiencing a 10% greater reduction in femoral bone mineral density (BMD) compared to WT mice (p<0.05). Bile acid metabolism was also profoundly affected; FGF15 KO mice displayed a 2.5-fold increase in circulating primary bile acids and a 40% decrease in conjugated bile acids, indicating significant dysregulation. The most striking finding was that daily administration of recombinant human FGF15 to FGF15 KO mice during weight loss completely rescued these phenotypes, leading to a 12% improvement in lean mass retention and normalizing bone mineral density to levels comparable to WT controls (p<0.001 for both). This intervention also restored bile acid profiles, reducing primary bile acids by 60% and increasing conjugated bile acids by 35%.
Why It Matters
These findings highlight FGF15 as a crucial endocrine factor that orchestrates beneficial adaptations in lean mass, bone, and bile acid metabolism during weight loss. The ability of exogenous FGF15 to mitigate the detrimental effects of caloric restriction on muscle and bone suggests its significant therapeutic potential. This research provides a strong rationale for developing FGF15-based therapies that could lead to novel strategies for preserving lean mass and bone health in individuals undergoing weight loss, particularly in clinical settings where sarcopenia or osteoporosis are concerns. Future steps should involve further preclinical validation in larger animal models and ultimately, progression to human clinical trials (e.g., Phase I/II) to assess safety and efficacy.